broad_id
string | depmap_id
string | ccle_name
string | screen_id
string | upper_limit
int64 | lower_limit
float64 | slope
float64 | r2
float64 | auc
float64 | ec50
float64 | ic50
float64 | name
string | moa
string | target
string | disease.area
string | indication
string | smiles
string | phase
string | passed_str_profiling
bool | row_name
string |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BRD-K99113996-001-02-0 | ACH-000936 | EFO27_OVARY | MTS010 | 1 | 0.465296 | 1.267569 | 0.609315 | 0.666107 | 0.023171 | 0.190093 | AZD2014 | mTOR inhibitor | MTOR | null | null | CNC(=O)c1cccc(c1)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C | Phase 2 | true | ACH-000936 |
BRD-K99616396-001-05-1 | ACH-000936 | EFO27_OVARY | MTS010 | 1 | 0.87318 | -1.382404 | 0.085735 | 0.915579 | 0.39304 | null | motesanib | KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | FLT1, FLT4, KDR, KIT | null | null | CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12 | Phase 3 | true | ACH-000936 |
BRD-K99749624-001-07-0 | ACH-000936 | EFO27_OVARY | MTS010 | 1 | 0.991166 | 0.238397 | -0.014096 | 0.992576 | 0.00004 | null | linifanib | PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK | null | null | Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)-c2cccc3[nH]nc(N)c23)c1 | Phase 3 | true | ACH-000936 |
BRD-M97302542-001-04-4 | ACH-000936 | EFO27_OVARY | MTS010 | 1 | 0.833351 | 1.186639 | 0.057865 | 0.984464 | 5.756072 | null | dichloroacetate | pyruvate dehydrogenase kinase inhibitor | PDK1 | null | null | [Na].OC(=O)C(Cl)Cl, [Na].OC(=O)C(Cl)Cl | Phase 3 | true | ACH-000936 |
BRD-A25234499-001-19-1 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 1.046639 | -0.191762 | 0.001712 | 1 | 0.291329 | null | aminoglutethimide | glucocorticoid receptor antagonist | CYP11A1, CYP19A1 | endocrinology, oncology | Cushing's syndrome, breast cancer | CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1 | Launched | true | ACH-000939 |
BRD-A70858459-001-01-7 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.686935 | 0.221892 | 0.13307 | 0.84713 | 0.098391 | null | estramustine | DNA alkylating agent | ESR1, ESR2, MAP1A, MAP2 | oncology | prostate cancer | C[C@]12CCC3C(CCc4cc(OC(=O)N(CCCl)CCCl)ccc34)C1CC[C@@H]2O | Launched | true | ACH-000939 |
BRD-A74914197-001-02-9 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.200213 | 1.995535 | 0.866689 | 0.571832 | 0.003462 | 0.004474 | pralatrexate | dihydrofolate reductase inhibitor | DHFR, TYMS | hematologic malignancy | peripheral T-cell lymphoma (PTCL) | Nc1nc(N)c2nc(CC(CC#C)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1 | Launched | true | ACH-000939 |
BRD-K02113016-001-19-6 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.54045 | 0.354457 | 0.232481 | 0.866645 | 1.693114 | null | olaparib | PARP inhibitor | PARP1, PARP2 | oncology | ovarian cancer | Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1, Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1 | Launched | true | ACH-000939 |
BRD-K02130563-001-11-4 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | -0.076444 | 0.686708 | 0.543345 | 0.70825 | 0.925245 | 0.752108 | panobinostat | HDAC inhibitor | HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9 | hematologic malignancy | multiple myeloma | Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1 | Launched | true | ACH-000939 |
BRD-K03390685-001-01-7 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 1.06447 | 0.444959 | -0.126183 | 1 | 0.315854 | null | cobimetinib | MEK inhibitor | null | oncology | melanoma | OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1 | Launched | true | ACH-000939 |
BRD-K03406345-001-21-1 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.867843 | 0.018111 | -0.021967 | 0.93038 | 0.000208 | null | azacitidine | DNA methyltransferase inhibitor | DNMT1, DNMT3A | hematologic malignancy, hematology | myelodysplastic diseases (MDS), anemia, chronic myelomonocytic leukemia (CMMoL) | Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000939 |
BRD-K03449891-001-08-6 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | -0.000393 | 0.66969 | 0.431508 | 0.86245 | 5.746235 | 5.739495 | foretinib | VEGFR inhibitor | FLT1, FLT4, KDR, MET | null | null | COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1 | Phase 2 | true | ACH-000939 |
BRD-K03765900-001-01-9 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.41419 | 0.334364 | 0.010335 | 0.788903 | 0.616811 | null | XL-647 | EGFR inhibitor, VEGFR inhibitor | EGFR, EPHB4, ERBB2, FLT4, KDR | null | null | COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@H]1C[C@H]2CN(C)C[C@H]2C1 | Phase 3 | true | ACH-000939 |
BRD-K05804044-001-18-5 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 1.031361 | -0.054977 | -0.008587 | 1 | 9.474016 | null | AZ-628 | RAF inhibitor | BRAF, RAF1 | null | null | Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1 | Preclinical | true | ACH-000939 |
BRD-K06814349-304-02-7 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.099065 | 2.645247 | 0.720143 | 0.784925 | 0.986766 | 1.072689 | fosbretabulin | tubulin polymerization inhibitor, VE-cadherin antagonist | CDH5 | null | null | COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O | Phase 3 | true | ACH-000939 |
BRD-K08109215-001-06-4 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.410281 | 1.267539 | 0.85863 | 0.749591 | 0.162897 | 0.631707 | I-BET-762 | bromodomain inhibitor | BRD2, BRD3, BRD4 | null | null | CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12 | Phase 2 | true | ACH-000939 |
BRD-K08542803-001-02-3 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.054659 | 3.499283 | 0.882048 | 0.652627 | 0.282674 | 0.292183 | gambogic-acid | caspase activator | BCL2 | null | null | CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C | Phase 2 | true | ACH-000939 |
BRD-K08547377-001-04-4 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.07039 | 2.306217 | 0.892854 | 0.564229 | 0.105756 | 0.112948 | irinotecan | topoisomerase inhibitor | TOP1, TOP1MT | oncology | colorectal cancer | CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12 | Launched | true | ACH-000939 |
BRD-K08703257-001-13-9 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.876125 | -0.365962 | -0.042268 | 0.933915 | 0.123462 | null | 3-amino-benzamide | PARP inhibitor | PARP1 | null | null | NC(=O)c1cccc(N)c1, NC(=O)c1cccc(N)c1 | Phase 2 | true | ACH-000939 |
BRD-K08799216-001-05-3 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | -0.005048 | 0.575369 | 0.709683 | 0.676948 | 0.582336 | 0.572258 | pelitinib | EGFR inhibitor | EGFR | null | null | CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C | Phase 2 | true | ACH-000939 |
BRD-K09951645-001-11-8 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 1.410339 | 0.364312 | -0.158391 | 1 | 0.043924 | null | dabrafenib | RAF inhibitor | BRAF, LIMK1, NEK11, RAF1, SIK1 | oncology | melanoma | CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F | Launched | true | ACH-000939 |
BRD-K11267252-001-05-1 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.850202 | 0.201687 | -0.003462 | 0.909429 | 0.008078 | null | alectinib | ALK tyrosine kinase receptor inhibitor | ALK, MET | oncology | non-small cell lung cancer (NSCLC) | CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1, CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1 | Launched | true | ACH-000939 |
BRD-K11630072-001-13-2 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.588078 | 0.874801 | 0.341141 | 0.918454 | 1.851033 | null | carmofur | thymidylate synthase inhibitor | TYMS | oncology | breast cancer, colorectal cancer | CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O | Launched | true | ACH-000939 |
BRD-K12184916-001-19-6 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.294746 | 0.667918 | 0.323699 | 0.517999 | 0.010623 | 0.040289 | NVP-BEZ235 | mTOR inhibitor, PI3K inhibitor | ATR, MTOR, PIK3CA, PIK3CD, PIK3CG | null | null | Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1, Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1 | Phase 2 | true | ACH-000939 |
BRD-K12343256-001-14-7 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 1.385568 | 1.360347 | 0.257031 | 1 | 0.904342 | null | trametinib | MEK inhibitor | MAP2K1, MAP2K2 | oncology | melanoma | CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O | Launched | true | ACH-000939 |
BRD-K13049116-001-04-0 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.160227 | 1.672206 | 0.579644 | 0.926732 | 5.063939 | 6.380044 | BMS-754807 | IGF-1 inhibitor | AKT1, IGF1R | null | null | C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1 | Phase 2 | true | ACH-000939 |
BRD-K13390322-001-06-3 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.083241 | 6.582067 | 0.808664 | 0.695904 | 0.399911 | 0.41113 | AT-7519 | CDK inhibitor | CDK1, CDK2, CDK4, CDK5, CDK6, CDK9 | null | null | Clc1cccc(Cl)c1C(=O)Nc1c[nH]nc1C(=O)NC1CCNCC1 | Phase 2 | true | ACH-000939 |
BRD-K13514097-001-04-6 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.831778 | -0.000703 | -0.001328 | 0.898816 | 19,323,071,736,725,780,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000 | null | everolimus | mTOR inhibitor | MTOR | oncology, neurology/psychiatry, genetics, urology | breast cancer, neuroendocrine tumors of pancreatic origin (PNET), renal cell carcinoma (RCC), subependymal giant cell astrocytoma (SEGA), tuberous sclerosis complex (TSC), renal angiomyolipoma | CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO | Launched | true | ACH-000939 |
BRD-K13662825-001-07-5 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.099518 | 3.463021 | 0.841406 | 0.446259 | 0.006413 | 0.006837 | dinaciclib | CDK inhibitor | CDK1, CDK2, CDK5, CDK9 | null | null | CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO | Phase 3 | true | ACH-000939 |
BRD-K14109347-001-03-4 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.045081 | 2.604201 | 0.926497 | 0.695118 | 0.451247 | 0.46791 | LY2603618 | CHK inhibitor | CHEK1 | null | null | Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1, Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1 | Phase 2 | true | ACH-000939 |
BRD-K15179879-001-03-2 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.125702 | 11.497031 | 0.860774 | 0.433498 | 0.018582 | 0.019056 | carfilzomib | proteasome inhibitor | PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9 | hematologic malignancy | multiple myeloma | CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1 | Launched | true | ACH-000939 |
BRD-K15600710-066-05-8 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.12591 | 8.239864 | 0.77829 | 0.70787 | 0.383232 | 0.396967 | obatoclax | BCL inhibitor | BCL2 | null | null | COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1, COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 | Phase 3 | true | ACH-000939 |
BRD-K17555800-003-02-3 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.784901 | -6.793623 | 0.30559 | 0.923155 | 0.019545 | null | talmapimod | p38 MAPK inhibitor | MAPK11, MAPK14 | null | null | C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C | Phase 2 | true | ACH-000939 |
BRD-K17610631-001-03-3 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.374466 | 3.590676 | 0.680663 | 0.790335 | 0.37453 | 0.550357 | indisulam | CDK inhibitor | CA1, CA12, CA14, CA2, CA6, CA7, CA9 | null | null | NS(=O)(=O)c1ccc(cc1)S(=O)(=O)Nc1cccc2c(Cl)c[nH]c12 | Phase 2 | true | ACH-000939 |
BRD-K17743125-001-08-4 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.223849 | 1.439341 | 0.557557 | 0.888247 | 2.732135 | 4.126954 | belinostat | HDAC inhibitor | HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9 | hematologic malignancy | peripheral T-cell lymphoma (PTCL) | ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc1ccccc1 | Launched | true | ACH-000939 |
BRD-K17894950-001-14-3 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 1.164748 | 0.592073 | 0.170853 | 1 | 0.221803 | null | indirubin | CDK inhibitor, glycogen synthase kinase inhibitor | CDK1, CDK5, GSK3A | null | null | O=C1Nc2ccccc2\C1=C1\Nc2ccccc2C1=O | Phase 2/Phase 3 | true | ACH-000939 |
BRD-K18961567-001-01-1 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.305336 | 0.694905 | 0.415828 | 0.791028 | 0.652559 | 2.536126 | LY2801653 | MET inhibitor | MET | null | null | Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1 | Phase 2 | true | ACH-000939 |
BRD-K19540840-001-09-4 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.849574 | -0.435711 | -0.059226 | 0.959081 | 0.003975 | null | saracatinib | src inhibitor | ABL1, LCK, SRC, YES1 | null | null | CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1 | Phase 2/Phase 3 | true | ACH-000939 |
BRD-K19687926-001-04-1 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 59.201713 | 0.75956 | -0.001732 | 1 | 8,467,641,589.78707 | null | lapatinib | EGFR inhibitor | EGFR, ERBB2 | oncology | breast cancer | CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1 | Launched | true | ACH-000939 |
BRD-K19796430-001-05-6 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.992779 | -0.100869 | -0.045077 | 0.996841 | 0.006136 | null | sonidegib | smoothened receptor antagonist | SMO | oncology | basal cell carcinoma (BCC) | C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1, C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1 | Launched | true | ACH-000939 |
BRD-K22064724-001-01-8 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.055009 | 0.968635 | 0.837748 | 0.604917 | 0.175763 | 0.198238 | napabucasin | STAT inhibitor | STAT3 | null | null | CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O, CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O | Phase 3 | true | ACH-000939 |
BRD-K22822991-001-02-3 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.906015 | -0.697684 | 0.255197 | 0.956672 | 0.052082 | null | odanacatib | cathepsin inhibitor | CTSK | null | null | CC(C)(F)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(cc1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N | Phase 3 | true | ACH-000939 |
BRD-K23228615-001-02-8 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.277502 | 0.711554 | 0.720029 | 0.721183 | 0.256281 | 0.799666 | GDC-0980 | mTOR inhibitor, PI3K inhibitor | FGR, MAP3K9, MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, SYK | null | null | C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1, C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1 | Phase 2 | true | ACH-000939 |
BRD-K23984367-001-07-5 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 1.069089 | -0.182242 | -0.021428 | 1 | 0.135528 | null | sorafenib | FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | BRAF, DDR2, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET | oncology | renal cell carcinoma (RCC), thyroid cancer, hepatocellular carcinoma (HCC) | CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1 | Launched | true | ACH-000939 |
BRD-K26026438-001-01-0 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.846445 | 4.070983 | 0.059388 | 0.88688 | 0.007855 | null | tucatinib | EGFR inhibitor | ERBB2 | null | null | Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1 | Phase 2 | true | ACH-000939 |
BRD-K26657438-001-15-2 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.832928 | 1.512897 | 0.109011 | 0.917936 | 0.085084 | null | imiquimod | interferon inducer, toll-like receptor agonist | TLR7, TLR8 | dermatology, infectious disease, oncology | actinic keratosis (AK), genital warts, basal cell carcinoma (BCC) | CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12 | Launched | true | ACH-000939 |
BRD-K28822270-001-03-7 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.235836 | 1.009185 | 0.427025 | 0.924145 | 6.394451 | null | resminostat | HDAC inhibitor | HDAC1, HDAC3, HDAC6, HDAC8 | null | null | CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO | Phase 2 | true | ACH-000939 |
BRD-K29905972-001-06-3 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.822919 | -1.696292 | 0.28521 | 0.877083 | 0.515867 | null | axitinib | PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1, FLT1, FLT4, KDR, PLK4 | oncology | renal cell carcinoma (RCC) | CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1 | Launched | true | ACH-000939 |
BRD-K30577245-001-05-0 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.246948 | 9.519969 | 0.608499 | 0.649694 | 0.006842 | 0.007349 | docetaxel | tubulin polymerization inhibitor | BCL2, MAP2, MAP4, MAPT, NR1I2, TUBB, TUBB1 | oncology | breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, gastric adenocarcinoma, head and neck squamous cell carcinoma (HNSCC) | CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C | Launched | true | ACH-000939 |
BRD-K31698212-001-02-9 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.952056 | -0.309991 | 0.002142 | 0.983819 | 0.006065 | null | icotinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | C#Cc1cccc(Nc2ncnc3cc4OCCOCCOCCOc4cc23)c1 | Launched | true | ACH-000939 |
BRD-K31928526-001-02-1 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.752437 | 0.427884 | 0.409378 | 0.871379 | 0.061178 | null | barasertib | Aurora kinase inhibitor | AURKA, AURKB | null | null | CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1)CCOP(O)(O)=O | Phase 2/Phase 3 | true | ACH-000939 |
BRD-K33379087-001-07-5 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.32191 | 4.579121 | 0.660007 | 0.769886 | 0.371299 | 0.465189 | tivantinib | tyrosine kinase inhibitor | MET | null | null | O=C1NC(=O)[C@H]([C@@H]1c1c[nH]c2ccccc12)c1cn2CCCc3cccc1c23 | Phase 3 | true | ACH-000939 |
BRD-K33610132-001-02-9 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.476319 | 0.510714 | 0.400528 | 0.819867 | 0.486754 | null | rociletinib | EGFR inhibitor | EGFR | null | null | COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O | Phase 3 | true | ACH-000939 |
BRD-K33622447-066-01-9 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | -0.029579 | 3.467478 | 0.632081 | 0.957673 | 7.292642 | 7.17276 | abemaciclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1 | Launched | true | ACH-000939 |
BRD-K36627727-001-05-4 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.96768 | 0.164443 | -0.00302 | 0.983159 | 0.045538 | null | tamibarotene | retinoid receptor agonist | RARA, RARB | hematologic malignancy | acute promyelocytic leukemia (APL) | CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(cc3)C(O)=O)ccc12 | Launched | true | ACH-000939 |
BRD-K36788280-001-01-2 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.882104 | -7.198803 | 0.191237 | 0.906191 | 1.376929 | null | ribociclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1 | Launched | true | ACH-000939 |
BRD-K37379014-001-02-0 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.294064 | 11.415012 | 0.683295 | 0.747869 | 0.004874 | 0.005268 | filanesib | kinesin inhibitor, kinesin-like spindle protein inhibitor | KIF11 | null | null | CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F, CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F | Phase 3 | true | ACH-000939 |
BRD-K38332599-001-01-3 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.566851 | 2.461716 | 0.551626 | 0.893104 | 0.912757 | null | uprosertib | AKT inhibitor | AKT1, AKT2, AKT3 | null | null | Cn1ncc(Cl)c1-c1cc(oc1Cl)C(=O)N[C@H](CN)Cc1ccc(F)c(F)c1 | Phase 2 | true | ACH-000939 |
BRD-K38527262-300-01-0 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.80965 | -5.931869 | 0.128455 | 0.952399 | 0.004498 | null | atiprimod | JAK inhibitor, STAT inhibitor | JAK2, STAT3 | null | null | CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1 | Phase 2 | true | ACH-000939 |
BRD-K38852836-001-02-1 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.105993 | 1.225073 | 0.823338 | 0.495608 | 0.010454 | 0.012698 | ganetespib | HSP inhibitor | HSP90AA1 | null | null | CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O | Phase 3 | true | ACH-000939 |
BRD-K39974922-001-04-3 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.805617 | 1.285936 | 0.051583 | 0.969755 | 2.491802 | null | lenvatinib | FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | FLT4, KDR | oncology | thyroid cancer | COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O | Launched | true | ACH-000939 |
BRD-K41859756-001-06-8 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.131763 | 3.568657 | 0.935643 | 0.480101 | 0.0075 | 0.008171 | NVP-AUY922 | HSP inhibitor | HSP90AA1, HSP90AB1 | null | null | CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O | Phase 2 | true | ACH-000939 |
BRD-K42495768-001-01-7 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.995388 | 0.366013 | -0.112357 | 0.998683 | 1.7091 | null | tasisulam | apoptosis stimulant | null | null | null | Clc1ccc(C(=O)NS(=O)(=O)c2ccc(Br)s2)c(Cl)c1 | Phase 3 | true | ACH-000939 |
BRD-K42805893-001-04-9 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 1.429224 | 1.929765 | 0.258033 | 1 | 3.230004 | null | osimertinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C)c2ccccc12 | Launched | true | ACH-000939 |
BRD-K42828737-001-03-3 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.995634 | 0.490916 | 0.004567 | 0.997124 | 0.006732 | null | sunitinib | FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | CSF1R, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB, RET | oncology | gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), neuroendocrine tumors of pancreatic origin (PNET) | CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C | Launched | true | ACH-000939 |
BRD-K42898655-001-01-8 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.912208 | -0.040617 | -0.004404 | 0.943553 | 9,960.511667 | null | temsirolimus | mTOR inhibitor | MTOR | oncology | renal cell carcinoma (RCC) | CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@@H]1OC(=O)C(C)(CO)CO | Launched | true | ACH-000939 |
BRD-K43389675-001-02-1 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.033412 | 1.135457 | 0.649264 | 0.482655 | 0.055329 | 0.058804 | daunorubicin | RNA synthesis inhibitor, topoisomerase inhibitor | TOP2A, TOP2B | hematologic malignancy | acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) | COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O | Launched | true | ACH-000939 |
BRD-K44227013-001-06-4 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.253937 | 1.851112 | 0.642125 | 0.839399 | 1.25224 | 1.836677 | ponatinib | Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor | ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK | hematologic malignancy | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) | CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1 | Launched | true | ACH-000939 |
BRD-K44408410-001-17-6 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.421088 | 0.260656 | 0.047542 | 0.750979 | 0.264037 | null | 2-methoxyestradiol | hypoxia inducible factor inhibitor | COMT, CYP19A1, CYP1A1, CYP1B1, HIF1A, TUBB | null | null | COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O | Phase 2 | true | ACH-000939 |
BRD-K46386702-001-02-1 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.685793 | -0.363608 | -0.025456 | 0.855681 | 0.044655 | null | ARRY-334543 | EGFR inhibitor | ERBB2 | null | null | C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1 | Phase 2 | true | ACH-000939 |
BRD-K49350383-001-14-5 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.219831 | 0.855612 | 0.230547 | 0.878283 | 3.194259 | 6.285953 | thioguanine | purine antagonist | IMPDH1, IMPDH2 | hematologic malignancy | acute myeloid leukemia (AML) | Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1 | Launched | true | ACH-000939 |
BRD-K50010139-001-01-5 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.734648 | 0.481743 | 0.091922 | 0.824595 | 0.011198 | null | poziotinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | null | null | COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C, COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C | Phase 2 | true | ACH-000939 |
BRD-K50168500-001-07-9 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.606682 | 5.997884 | 0.651764 | 0.896889 | 0.785417 | null | canertinib | EGFR inhibitor | AKT1, EGFR, ERBB2, ERBB4 | null | null | Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl | Phase 3 | true | ACH-000939 |
BRD-K51313569-001-07-8 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | -0.72184 | 2.678324 | 0.308631 | 0.978111 | 14.191626 | null | palbociclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O, CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O | Launched | true | ACH-000939 |
BRD-K51791723-003-01-7 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.092746 | 5.276032 | 0.770788 | 0.723709 | 0.520573 | 0.541219 | P276-00 | CDK inhibitor | CDK1, CDK4, CDK9 | null | null | CN1CC[C@H]([C@@H]1CO)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl | Phase 2 | true | ACH-000939 |
BRD-K51967704-001-03-6 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.110908 | 2.527615 | 0.806529 | 0.669017 | 0.269787 | 0.297929 | BIIB021 | HSP inhibitor | HSP90AA1 | null | null | COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C, COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C | Phase 2 | true | ACH-000939 |
BRD-K52313696-001-12-3 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 1.15292 | 2.522842 | 0.254163 | 1 | 0.262879 | null | tacedinaline | HDAC inhibitor | HDAC1 | null | null | CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N, CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N | Phase 3 | true | ACH-000939 |
BRD-K53414658-001-08-2 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.552649 | 1.739123 | 0.322868 | 0.941086 | 2.975602 | null | tivozanib | VEGFR inhibitor | FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB | null | null | COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC | Phase 3 | true | ACH-000939 |
BRD-K53972329-001-07-0 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.882217 | -2.545424 | -0.02599 | 0.891376 | 5.003596 | null | ruxolitinib | JAK inhibitor | JAK1, JAK2, JAK3, TYK2 | hematologic malignancy, hematology | myelofibrosis, polycythemia vera | N#CC[C@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12 | Launched | true | ACH-000939 |
BRD-K54256913-001-08-7 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.053645 | 3.529243 | 0.893513 | 0.737758 | 0.679352 | 0.701564 | MK-1775 | WEE1 kinase inhibitor | WEE1 | null | null | CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n(-c2cccc(n2)C(C)(C)O)n(CC=C)c3=O)cc1 | Phase 2 | true | ACH-000939 |
BRD-K54955827-001-02-2 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.056054 | 1.715074 | 0.670452 | 0.882959 | 3.249369 | 3.48267 | niraparib | PARP inhibitor | PARP1 | oncology | primary peritoneal cancer (PPC) | NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1, NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1 | Launched | true | ACH-000939 |
BRD-K54997624-001-06-0 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.379053 | 1.285109 | 0.648298 | 0.753784 | 0.214309 | 0.646653 | alpelisib | PI3K inhibitor | PIK3CA, PIK3CB, PIK3CD, PIK3CG | null | null | Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(c1)C(C)(C)C(F)(F)F | Phase 3 | true | ACH-000939 |
BRD-K55187425-236-05-2 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.204015 | 1.702336 | 0.773989 | 0.514925 | 0.026988 | 0.036723 | rigosertib | cell cycle inhibitor, PLK inhibitor | PLK1 | null | null | COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1 | Phase 3 | true | ACH-000939 |
BRD-K56343971-001-14-8 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 1.114232 | -0.011923 | -0.00512 | 1 | 12,102,397.943392 | null | vemurafenib | RAF inhibitor | BRAF, RAF1 | oncology | melanoma | CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F | Launched | true | ACH-000939 |
BRD-K56981171-001-02-8 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.700406 | 0.478228 | 0.463035 | 0.87201 | 0.185357 | null | brigatinib | ALK tyrosine kinase receptor inhibitor, EGFR inhibitor | ALK, EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1 | Launched | true | ACH-000939 |
BRD-K57080016-001-15-9 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.852417 | -6.187742 | 0.365401 | 0.864473 | 4.531315 | null | selumetinib | MEK inhibitor | MAP2K1 | null | null | Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO | Phase 3 | true | ACH-000939 |
BRD-K57169635-001-04-5 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | -0.007879 | 0.959834 | 0.52648 | 0.864437 | 3.847637 | 3.785423 | dacomitinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | null | null | COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN1CCCCC1 | Phase 3 | true | ACH-000939 |
BRD-K58435339-001-03-0 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.076387 | 0.406764 | 0.795915 | 0.485112 | 0.037259 | 0.056007 | AT13387 | HSP antagonist | HSP90AA1 | null | null | CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O, CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O | Phase 2 | true | ACH-000939 |
BRD-K58529924-001-01-5 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.290702 | 0.399191 | 0.297007 | 0.706281 | 0.254413 | 2.254075 | ONC201 | AKT inhibitor, MAP kinase inhibitor | TNFSF10 | null | null | Cc1ccccc1CN1C2=NCCN2C2=C(CN(Cc3ccccc3)CC2)C1=O | Phase 2 | true | ACH-000939 |
BRD-K58550667-001-08-7 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.14211 | 4.000186 | 0.743449 | 0.650062 | 0.011928 | 0.012968 | FK-866 | niacinamide phosphoribosyltransferase inhibitor | NAMPT | null | null | O=C(NCCCCC1CCN(CC1)C(=O)c1ccccc1)\C=C\c1cccnc1 | Phase 2 | true | ACH-000939 |
BRD-K59317601-001-05-5 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.2376 | 0.480359 | 0.692774 | 0.602693 | 0.06087 | 0.232978 | MLN0128 | mTOR inhibitor | MTOR, PIK3CA, PIK3CD, PIK3CG | null | null | CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc12 | Phase 2 | true | ACH-000939 |
BRD-K59369769-001-22-9 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.654518 | 0.244665 | 0.120252 | 0.855086 | 0.342918 | null | tozasertib | Aurora kinase inhibitor, Bcr-Abl kinase inhibitor, FLT3 inhibitor, JAK inhibitor | AURKA, AURKB, AURKC, LCK | null | null | CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1, CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1 | Phase 2 | true | ACH-000939 |
BRD-K60866521-001-07-1 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.758789 | -0.004543 | -0.052545 | 0.878839 | 0.594106 | null | idelalisib | PI3K inhibitor | PIK3CA, PIK3CB, PIK3CD, PIK3CG | hematologic malignancy | chronic lymphocytic leukemia (CLL) | CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1 | Launched | true | ACH-000939 |
BRD-K60997853-001-02-3 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.093233 | 2.299473 | 0.666379 | 0.887124 | 3.07235 | 3.360831 | PHA-848125 | CDK inhibitor, growth factor receptor inhibitor | CDK2, CDK4, CDK7, NTRK1 | null | null | CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21 | Phase 2 | true | ACH-000939 |
BRD-K61192372-001-08-9 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.961784 | -0.160184 | -0.031284 | 0.979111 | 0.26586 | null | capecitabine | DNA synthesis inhibitor, thymidylate synthase inhibitor | TYMS | oncology | breast cancer, colorectal cancer | CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O | Launched | true | ACH-000939 |
BRD-K62008436-001-23-9 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.094313 | 6.898111 | 0.865083 | 0.589515 | 0.007683 | 0.007919 | paclitaxel | tubulin polymerization inhibitor | BCL2, MAP2, MAP4, MAPT, NR1I2, TLR4, TUBB, TUBB1 | oncology | ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC) | CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1 | Launched | true | ACH-000939 |
BRD-K62196610-001-01-6 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.320281 | 4.02354 | 0.815032 | 0.786148 | 0.472048 | 0.608741 | AVN-944 | inosine monophosphate dehydrogenase inhibitor | IMPDH1, IMPDH2 | null | null | CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1 | Phase 2 | true | ACH-000939 |
BRD-K62200014-003-10-5 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.96679 | -0.487932 | -0.014475 | 0.985205 | 0.041183 | null | anagrelide | phosphodiesterase inhibitor | PDE3A | hematology, hematologic malignancy | thrombocythemia, myeloproliferative neoplasms | Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl | Launched | true | ACH-000939 |
BRD-K62391742-001-09-7 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 0.978803 | -0.213059 | 0.006212 | 0.986942 | 0.869541 | null | venetoclax | BCL inhibitor | BCL2 | hematologic malignancy | chronic lymphocytic leukemia (CLL) | CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1 | Launched | true | ACH-000939 |
BRD-K62627508-001-01-5 | ACH-000939 | SKUT1_SOFT_TISSUE | MTS010 | 1 | 1.269911 | 3.200791 | 0.347839 | 1 | 0.449004 | null | idasanutlin | MDM inhibitor | MDM2, TP53 | null | null | COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O | Phase 3 | true | ACH-000939 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.